Acrobiosystems Co.,Ltd. (SHE:301080)

China · Delayed Price · Currency is CNY

53.31

+3.08 (6.13%)

At close: Jul 14, 2026

7.35% (1Y)

Market Cap	8.91B +33.5%
Revenue (ttm)	887.21M +29.4%
Net Income	171.25M +28.0%
EPS	1.04 +32.4%
Shares Out	167.18M
PE Ratio	51.31
Forward PE	30.82
Dividend	0.60 (1.19%)
Ex-Dividend Date	Jun 11, 2026

Volume	10,053,042
Open	50.22
Previous Close	50.23
Day's Range	49.36 - 54.47
52-Week Range	35.87 - 71.49
Beta	0.64
Analysts	Strong Buy
Price Target	72.94 (+36.82%)
Earnings Date	Aug 29, 2026

About Acrobiosystems

Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and research institutions. It provides kits, scientific services, and other related products under the Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, and GENPower brands. The company also offers cell therapies, gene therapies, therapeutic antibodies, antibody-drug conjugates, core reagents for infectious disease research, and solutions fo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 926

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301080

Full Company Profile

Financial Performance

In 2025, Acrobiosystems's revenue was 838.12 million, an increase of 29.94% compared to the previous year's 645.02 million. Earnings were 165.57 million, an increase of 33.70%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for 301080 stock is "Strong Buy." The 12-month stock price target is ¥72.94, which is an increase of 36.82% from the latest price.

Price Target

¥72.94

(36.82% upside)

Analyst Consensus: Strong Buy

Stock Forecasts